{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:57:49Z","timestamp":1791849469960,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bacterial vaginosis (BV) is associated with HIV acquisition and adverse pregnancy outcomes. Recurrence after metronidazole treatment is high. HIV-negative, non-pregnant Rwandan BV patients were randomized to four groups (n = 17\/group) after seven-day oral metronidazole treatment: behavioral counseling only (control), or counseling plus intermittent use of oral metronidazole, Ecologic Femi+ vaginal capsule (containing multiple\n                    <jats:italic>Lactobacillus<\/jats:italic>\n                    and one\n                    <jats:italic>Bifidobacterium<\/jats:italic>\n                    species), or Gynophilus LP vaginal tablet (\n                    <jats:italic>L. rhamnosus<\/jats:italic>\n                    35) for two months. Vaginal microbiota assessments at all visits included Gram stain Nugent scoring and 16S rRNA gene qPCR and HiSeq sequencing. All interventions were safe. BV (Nugent 7\u201310) incidence was 10.18 per person-year at risk in the control group, and lower in the metronidazole (1.41\/person-year; p = 0.004), Ecologic Femi+ (3.58\/person-year; p = 0.043), and Gynophilus LP groups (5.36\/person-year; p = 0.220). In mixed effects models adjusted for hormonal contraception\/pregnancy, sexual risk-taking, and age, metronidazole and Ecologic Femi+ users, each compared to controls, had higher\n                    <jats:italic>Lactobacillus<\/jats:italic>\n                    and lower BV-anaerobes estimated concentrations and\/or relative abundances, and were less likely to have a dysbiotic vaginal microbiota type by sequencing. Inter-individual variability was high and effects disappeared soon after intervention cessation. Lactobacilli-based vaginal probiotics warrant further evaluation because, in contrast to antibiotics, they are not expected to negatively affect gut microbiota or cause antimicrobial resistance.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-60671-6","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T06:03:21Z","timestamp":1583215401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Intermittent Lactobacilli-containing Vaginal Probiotic or Metronidazole Use to Prevent Bacterial Vaginosis Recurrence: A Pilot Study Incorporating Microscopy and Sequencing"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2728-4560","authenticated-orcid":false,"given":"Janneke H. H. M.","family":"van de Wijgert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijn C.","family":"Verwijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Agaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bronowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Mwambarangwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Uwineza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Lievens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Nivoliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-2233","authenticated-orcid":false,"given":"Jacques","family":"Ravel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3786-6209","authenticated-orcid":false,"given":"Alistair C.","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"60671_CR1","doi-asserted-by":"publisher","first-page":"e105998","DOI":"10.1371\/journal.pone.0105998","volume":"9","author":"JHHM van de Wijgert","year":"2014","unstructured":"van de Wijgert, J. H. H. M. et al. The vaginal microbiota: what have we learned after a decade of molecular characterization? PLoS One 9, e105998 (2014).","journal-title":"PLoS One"},{"key":"60671_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.resmic.2017.02.003","volume":"168","author":"JHHM van de Wijgert","year":"2017","unstructured":"van de Wijgert, J. H. H. M. & Jespers, V. The global health impact of vaginal dysbiosis. Res. Microbiol. 168, 859\u2013864 (2017).","journal-title":"Res. Microbiol."},{"key":"60671_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/mi.2015.86","volume":"9","author":"H Borgdorff","year":"2016","unstructured":"Borgdorff, H. et al. Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervicovaginal mucosal barrier. Mucosal Immunol. 9, 621\u2013633 (2016).","journal-title":"Mucosal Immunol."},{"key":"60671_CR4","unstructured":"World Health Organization. Guidelines for the management of sexually transmitted infections, http:\/\/applications.emro.who.int\/aiecf\/web79.pdf (2003)."},{"key":"60671_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1128\/JCM.29.2.297-301.1991","volume":"29","author":"RP Nugent","year":"1991","unstructured":"Nugent, R. P., Krohn, M. A. & Hillier, S. L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J. Clin. Microbiol. 29, 297\u2013301 (1991).","journal-title":"J. Clin. Microbiol."},{"key":"60671_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0002-9343(83)91112-9","volume":"74","author":"R Amsel","year":"1983","unstructured":"Amsel, R. et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am. J. Med. 74, 14\u201322 (1983).","journal-title":"Am. J. Med."},{"key":"60671_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/QCO.0b013e32832180c6","volume":"22","author":"P Hay","year":"2009","unstructured":"Hay, P. Recurrent bacterial vaginosis. Curr. Opin. Infect. Dis. 22, 82\u201386 (2009).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"60671_CR8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1586\/eri.09.87","volume":"7","author":"H Verstraelen","year":"2009","unstructured":"Verstraelen, H. & Verhelst, R. Bacterial vaginosis: an update on diagnosis and treatment. Expert Rev. Anti Infect. Ther. 7, 1109\u20131124 (2009).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"60671_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/OGX.0b013e3181e09621","volume":"65","author":"G Donders","year":"2010","unstructured":"Donders, G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet. Gynecol. Surv. 65, 462 (2010).","journal-title":"Obstet. Gynecol. Surv."},{"key":"60671_CR10","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ajog.2005.11.041","volume":"194","author":"JD Sobel","year":"2006","unstructured":"Sobel, J. D. et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am. J. Obstet. Gynecol. 194, 1283\u20131289 (2006).","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"60671_CR11","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1371\/journal.pctr.0020010","volume":"2","author":"Taha E Taha","year":"2007","unstructured":"Taha, T. E. et al. Intermittent intravaginal antibiotic treatment of bacterial vaginosis in HIV-uninfected and -infected women: a randomized clinical trial. PLoS Clin. Trials 2 (2007).","journal-title":"PLoS Clinical Trials"},{"key":"60671_CR12","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1086\/587490","volume":"197","author":"RS McClelland","year":"2008","unstructured":"McClelland, R. S. et al. Improvement of vaginal health for Kenyan women at risk for acquisition of Human Immunodeficiency Virus type 1: results of a randomized trial. J. Infect. Dis. 197, 1361\u20131368 (2008).","journal-title":"J. Infect. Dis."},{"key":"60671_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1469-0691.2008.02112.x","volume":"15","author":"P Mastromarino","year":"2009","unstructured":"Mastromarino, P. et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin. Microbiol. Infect. 15, 67\u201374 (2009).","journal-title":"Clin. Microbiol. Infect."},{"key":"60671_CR14","doi-asserted-by":"crossref","unstructured":"Larsson, P.-G., Stray-Pedersen, B., Ryttig, K. R. & Larsen, S. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health 8 (2008).","DOI":"10.1186\/1472-6874-8-3"},{"key":"60671_CR15","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/j.1471-0528.2008.01882.x","volume":"115","author":"L Petricevic","year":"2008","unstructured":"Petricevic, L. & Witt, A. The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. Br. J. Obstet. Gynaecol. 115, 1369\u20131374 (2008).","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"60671_CR16","doi-asserted-by":"publisher","first-page":"e34540","DOI":"10.1371\/journal.pone.0034540","volume":"7","author":"CS Bradshaw","year":"2012","unstructured":"Bradshaw, C. S. et al. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. PLoS One 7, e34540 (2012).","journal-title":"PLoS One"},{"key":"60671_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/00015550410022249","volume":"85","author":"K Eriksson","year":"2005","unstructured":"Eriksson, K., Carlsson, B., Forsum, U. & Larsson, P.-G. A double-blind treatment study of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovules. Acta Derm. Venereol. 85, 42\u201346 (2005).","journal-title":"Acta Derm. Venereol."},{"key":"60671_CR18","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1016\/j.micinf.2006.08.008","volume":"8","author":"KC Anukam","year":"2006","unstructured":"Anukam, K. C. et al. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 8, 2772\u20132776 (2006).","journal-title":"Microbes Infect."},{"key":"60671_CR19","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1007\/s10096-012-1671-1","volume":"31","author":"R Hemalatha","year":"2012","unstructured":"Hemalatha, R., Mastromarino, P., Ramalaxmi, B. A., Balakrishna, N. V. & Sesikeran, B. Effectiveness of vaginal tablets containing lactobacilli versus pH tablets on vaginal health and inflammatory cytokines: a randomized, double-blind study. Eur. J. Clin. Microbiol. Infect. Dis. 31, 3097\u20133105 (2012).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"60671_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00248-012-0154-3","volume":"65","author":"Z Ling","year":"2013","unstructured":"Ling, Z. et al. The restoration of the vaginal microbiota after treatment for bacterial vaginosis with metronidazole or probiotics. Microb. Ecol. 65, 773\u2013780 (2013).","journal-title":"Microb. Ecol."},{"key":"60671_CR21","doi-asserted-by":"publisher","first-page":"e104511","DOI":"10.1371\/journal.pone.0104511","volume":"9","author":"JE Bisanz","year":"2014","unstructured":"Bisanz, J. E. et al. A systems biology approach investigating the effect of probiotics on the vaginal microbiome and host responses in a double blind, placebo-controlled clinical trial of post-menopausal women. PLoS One 9, e104511 (2014).","journal-title":"PLoS One"},{"key":"60671_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00284-016-1085-x","volume":"73","author":"MC Verdenelli","year":"2016","unstructured":"Verdenelli, M. C. et al. Impact of probiotic SYNBIO\u00ae administered by vaginal suppositories in promoting vaginal health of apparently healthy women. Curr. Microbiol. 73, 483\u2013490 (2016).","journal-title":"Curr. Microbiol."},{"key":"60671_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jogoh.2017.11.005","volume":"47","author":"JM Bohbot","year":"2018","unstructured":"Bohbot, J. M. et al. Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. J. Gynecol. Obstet. Hum. Reprod. 47, 81\u201386 (2018).","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"60671_CR24","first-page":"21","volume":"30","author":"AMC Rapisarda","year":"2018","unstructured":"Rapisarda, A. M. C. et al. Efficacy of vaginal preparation containing Lactobacillus acidophilus, lactic acid and deodorized garlic extract in treatment and prevention of symptomatic bacterial vaginitis: result from a single-arm pilot study. Ital. J. Gynaecol. Obstet. 30, 21\u201331 (2018).","journal-title":"Ital. J. Gynaecol. Obstet."},{"key":"60671_CR25","doi-asserted-by":"publisher","first-page":"17057","DOI":"10.1038\/nmicrobiol.2017.57","volume":"2","author":"PW O\u2019Toole","year":"2017","unstructured":"O\u2019Toole, P. W., Marchesi, J. R. & Hill, C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat. Microbiol. 2, 17057 (2017).","journal-title":"Nat. Microbiol."},{"key":"60671_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1471-2180-12-56","volume":"12","author":"CM Liu","year":"2012","unstructured":"Liu, C. M. et al. BactQuant: an enhanced broad-coverage bacterial quantitative real-time PCR assay. BMC Microbiol. 12, 56 (2012).","journal-title":"BMC Microbiol."},{"key":"60671_CR27","unstructured":"Keystone Symposia | Scientific Conferences on Biomedical and Life Science Topics, https:\/\/www.keystonesymposia.org\/18S6."},{"key":"60671_CR28","doi-asserted-by":"publisher","unstructured":"Jian, C., Luukkonen, P., Yki-Jarvinen, H., Salonen, A. & Korpela, K. Quantitative PCR provides a simple and accessible method for quantitative microbiome profiling: bioRxiv, https:\/\/doi.org\/10.1101\/478685 (2018).","DOI":"10.1101\/478685"},{"key":"60671_CR29","doi-asserted-by":"publisher","first-page":"e1002478","DOI":"10.1371\/journal.pmed.1002478","volume":"14","author":"JHHM van de Wijgert","year":"2017","unstructured":"van de Wijgert, J. H. H. M. The vaginal microbiome and sexually transmitted infections are interlinked: consequences for treatment and prevention. PLoS Med. 14, e1002478 (2017).","journal-title":"PLoS Med."},{"key":"60671_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(02)07683-3","volume":"359","author":"KF Schulz","year":"2002","unstructured":"Schulz, K. F. & Grimes, D. A. Generation of allocation sequences in randomised trials: chance, not choice. Lancet 359, 515\u2013519 (2002).","journal-title":"Lancet"},{"key":"60671_CR31","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1128\/JCM.41.5.1881-1887.2003","volume":"41","author":"MAD Antonio","year":"2003","unstructured":"Antonio, M. A. D. & Hillier, S. L. DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J. Clin. Microbiol. 41, 1881\u20131887 (2003).","journal-title":"J. Clin. Microbiol."},{"key":"60671_CR32","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1086\/598686","volume":"199","author":"MAD Antonio","year":"2009","unstructured":"Antonio, M. A. D., Meyn, L. A., Murray, P. J., Busse, B. & Hillier, S. L. Vaginal colonization by probiotic Lactobacillus crispatus CTV\u201005 is decreased by sexual activity and endogenous lactobacilli. J. Infect. Dis. 199, 1506\u20131513 (2009).","journal-title":"J. Infect. Dis."},{"key":"60671_CR33","doi-asserted-by":"publisher","unstructured":"Tomusiak, A. et al. Efficacy and safety of a vaginal medicinal product containing three strains of probiotic bacteria: a multicenter, randomized, double-blind, and placebo-controlled trial. Drug Des. Devel. Ther. 5345, https:\/\/doi.org\/10.2147\/DDDT.S89214 (2015).","DOI":"10.2147\/DDDT.S89214"},{"key":"60671_CR34","doi-asserted-by":"publisher","first-page":"e1002533","DOI":"10.1371\/journal.pbio.1002533","volume":"14","author":"R Sender","year":"2016","unstructured":"Sender, R., Fuchs, S. & Milo, R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533 (2016).","journal-title":"PLoS Biol."},{"key":"60671_CR35","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s10096-018-3321-8","volume":"37","author":"C Dausset","year":"2018","unstructured":"Dausset, C. et al. Comparative phase I randomized open-label pilot clinical trial of Gynophilus\u00ae (Lcr regenerans\u00ae) immediate release capsules versus slow release muco-adhesive tablets. Eur. J. Clin. Microbiol. Infect. Dis. 37, 1869\u20131880 (2018).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"8","key":"60671_CR36","doi-asserted-by":"publisher","first-page":"e0161337","DOI":"10.1371\/journal.pone.0161337","volume":"11","author":"Mariya I. Petrova","year":"2016","unstructured":"Petrova, M. I. et al. Lectin-like molecules of Lactobacillus rhamnosus GG inhibit pathogenic Escherichia coli and Salmonella biofilm formation. PLoS One 11 (2016).","journal-title":"PLOS ONE"},{"key":"60671_CR37","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.resmic.2017.04.001","volume":"168","author":"G Tachedjian","year":"2017","unstructured":"Tachedjian, G., Aldunate, M., Bradshaw, C. S. & Cone, R. A. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res. Microbiol. 168, 782\u2013792 (2017).","journal-title":"Res. Microbiol."},{"key":"60671_CR38","doi-asserted-by":"publisher","first-page":"132ra52","DOI":"10.1126\/scitranslmed.3003605","volume":"4","author":"P Gajer","year":"2012","unstructured":"Gajer, P. et al. Temporal dynamics of the human vaginal microbiota. Sci. Transl. Med. 4, 132ra52\u2013132ra52 (2012).","journal-title":"Sci. Transl. Med."},{"key":"60671_CR39","doi-asserted-by":"publisher","first-page":"e0181135","DOI":"10.1371\/journal.pone.0181135","volume":"12","author":"H Borgdorff","year":"2017","unstructured":"Borgdorff, H. et al. The association between ethnicity and vaginal microbiota composition in Amsterdam, the Netherlands. PLoS One 12, e0181135 (2017).","journal-title":"PLoS One"},{"key":"60671_CR40","doi-asserted-by":"crossref","unstructured":"Noyes, N., Cho, K.-C., Ravel, J., Forney, L. J. & Abdo, Z. Associations between sexual habits, menstrual hygiene practices, demographics and the vaginal microbiome as revealed by Bayesian network analysis. PLoS One 13 (2018).","DOI":"10.1371\/journal.pone.0191625"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60671-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60671-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60671-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:30:23Z","timestamp":1670293823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60671-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60671"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60671-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/19001156","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.737483874.793592076","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"20 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AN is employed by Biose (owner of trial product GynLP) and EL by Winclove Probiotics BV (owner of trial product EF+). AN and JR have financial and\/or intellectual investments in competing products. The other authors report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3884"}}